What is Vasodil used for?

Vasodil is indicated for Cerebrovascular disease, Disorder of blood vessel, Persistent pulmonary hypertension of the newborn.

Vasodil is developed by Novartis.

What development phase is Vasodil in?

Vasodil is FDA-approved (marketed).

What is the generic name of Vasodil?

TOLAZOLINE is the generic (nonproprietary) name of Vasodil.

Last reviewed 2026-04-20 · How we verify

Vasodil (TOLAZOLINE)

Novartis · FDA-approved approved Small molecule Quality 25/100

Vasodil (TOLAZOLINE) is a small molecule drug developed by NOVARTIS that targets the Alpha-2A adrenergic receptor. It is classified as a tolazoline and was first approved by the FDA in 1948 for the treatment of cerebrovascular disease, disorders of blood vessels, and persistent pulmonary hypertension of the newborn. As an off-patent medication with no active Orange Book patents, Vasodil is available without generic competition. Key safety considerations include the need for careful dosing and monitoring due to its potent vasodilatory effects. NOVARTIS remains the current owner of the medication.

At a glance

Generic name	TOLAZOLINE
Sponsor	Novartis
Drug class	tolazoline
Target	Alpha-2A adrenergic receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved
First approval	1948

Approved indications

Cerebrovascular disease
Disorder of blood vessel
Persistent pulmonary hypertension of the newborn

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vasodil CI brief — competitive landscape report
Vasodil updates RSS · CI watch RSS
Novartis portfolio CI